123 related articles for article (PubMed ID: 32823970)
1. Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies.
Snow O; Lallous N; Ester M; Cherkasov A
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823970
[TBL] [Abstract][Full Text] [Related]
2. Cheminformatics Modeling of Adverse Drug Responses by Clinically Relevant Mutants of Human Androgen Receptor.
Paul N; Carabet LA; Lallous N; Yamazaki T; Gleave ME; Rennie PS; Cherkasov A
J Chem Inf Model; 2016 Dec; 56(12):2507-2516. PubMed ID: 28024400
[TBL] [Abstract][Full Text] [Related]
3. Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.
Sugawara T; Baumgart SJ; Nevedomskaya E; Reichert K; Steuber H; Lejeune P; Mumberg D; Haendler B
Int J Cancer; 2019 Sep; 145(5):1382-1394. PubMed ID: 30828788
[TBL] [Abstract][Full Text] [Related]
4. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
Rosati R; Polin L; Ducker C; Li J; Bao X; Selvakumar D; Kim S; Xhabija B; Larsen M; McFall T; Huang Y; Kidder BL; Fribley A; Saxton J; Kakuta H; Shaw P; Ratnam M
Clin Cancer Res; 2018 Dec; 24(24):6509-6522. PubMed ID: 30185422
[TBL] [Abstract][Full Text] [Related]
5. 2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways.
Shah S; Hess-Wilson JK; Webb S; Daly H; Godoy-Tundidor S; Kim J; Boldison J; Daaka Y; Knudsen KE
Mol Cancer Res; 2008 Sep; 6(9):1507-20. PubMed ID: 18819937
[TBL] [Abstract][Full Text] [Related]
6. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.
Moilanen AM; Riikonen R; Oksala R; Ravanti L; Aho E; Wohlfahrt G; Nykänen PS; Törmäkangas OP; Palvimo JJ; Kallio PJ
Sci Rep; 2015 Jul; 5():12007. PubMed ID: 26137992
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor antagonists for prostate cancer therapy.
Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
[TBL] [Abstract][Full Text] [Related]
8. Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
Yu J; Zhou P; Hu M; Yang L; Yan G; Xu R; Deng Y; Li X; Chen Y
Eur J Med Chem; 2019 Nov; 182():111608. PubMed ID: 31437779
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Liu Y; Majumder S; McCall W; Sartor CI; Mohler JL; Gregory CW; Earp HS; Whang YE
Cancer Res; 2005 Apr; 65(8):3404-9. PubMed ID: 15833875
[TBL] [Abstract][Full Text] [Related]
10. Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor.
Radaeva M; Ban F; Zhang F; LeBlanc E; Lallous N; Rennie PS; Gleave ME; Cherkasov A
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33801338
[TBL] [Abstract][Full Text] [Related]
11. Metabolically stable diphenylamine derivatives suppress androgen receptor and BET protein in prostate cancer.
Yu J; Zhou P; Du W; Xu R; Yan G; Deng Y; Li X; Chen Y
Biochem Pharmacol; 2020 Jul; 177():113946. PubMed ID: 32247852
[TBL] [Abstract][Full Text] [Related]
12. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells.
Liu P; Li S; Gan L; Kao TP; Huang H
Cancer Res; 2008 Dec; 68(24):10290-9. PubMed ID: 19074897
[TBL] [Abstract][Full Text] [Related]
13. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
[TBL] [Abstract][Full Text] [Related]
14. A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells.
Auvin S; Öztürk H; Abaci YT; Mautino G; Meyer-Losic F; Jollivet F; Bashir T; de Thé H; Sahin U
Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31431473
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line.
Marcias G; Erdmann E; Lapouge G; Siebert C; Barthélémy P; Duclos B; Bergerat JP; Céraline J; Kurtz JE
Hum Mutat; 2010 Jan; 31(1):74-80. PubMed ID: 19830810
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
[TBL] [Abstract][Full Text] [Related]
17. Androgen axis in prostate cancer.
Culig Z; Bartsch G
J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
[TBL] [Abstract][Full Text] [Related]
18. Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.
Divakar S; Saravanan K; Karthikeyan P; Elancheran R; Kabilan S; Balasubramanian KK; Devi R; Kotoky J; Ramanathan M
Chem Biol Interact; 2017 Sep; 275():22-34. PubMed ID: 28757136
[TBL] [Abstract][Full Text] [Related]
19. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.
Chatterjee B
Mol Cell Biochem; 2003 Nov; 253(1-2):89-101. PubMed ID: 14619959
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.
Tam KJ; Dalal K; Hsing M; Cheng CW; Khosravi S; Yenki P; Tse C; Peacock JW; Sharma A; Chiang YT; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
Oncotarget; 2017 Feb; 8(6):9617-9633. PubMed ID: 28038451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]